GLP-1 Family advanced
GLP-1 Agonists in NASH/MASH Treatment
Efficacy of GLP-1 receptor agonists in nonalcoholic steatohepatitis including histological improvements.
By Encyclopeptide Editorial | 1 min read
GLP-1 NASH MASH liver-disease steatohepatitis
Clinical Evidence
Semaglutide (Phase 2)
- NASH resolution without worsening fibrosis: 59% (2.4 mg) vs 17% (placebo)
- Reduced liver fat content by 70-80%
Liraglutide (LEAN Trial)
- NASH resolution: 39% vs 9% (placebo)
Mechanisms in NASH
- Reduced hepatic de novo lipogenesis
- Improved insulin sensitivity
- Weight loss reducing visceral adiposity
- Anti-inflammatory effects
Chemical Identity
| Property | Value |
|---|---|
| Name | GLP-1 Agonists in NASH/MASH Treatment |
| Category | GLP-1 Family |
References
- Encyclopeptide Database. “GLP-1 Agonists in NASH/MASH Treatment” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about GLP-1 Agonists in NASH/MASH Treatment with interactive quizzes on Wikipept.
Take a Quiz on Wikipept